10-Q: Jackson Acquisition II Reports Q2 Net Income

Jackson Acquisition Company II, a SPAC targeting healthcare, reported a net income of $2.3 million for Q2 2025, primarily from interest on its $237.7 million trust account.

Summary

• Reported net income of $2,318,336 for the three months ended June 30, 2025, and $4,545,737 for the six months ended June 30, 2025.
• Interest earned on marketable securities in the Trust Account was the primary source of income, totaling $2,447,373 for Q2 2025 and $4,881,095 for the six months.
• General and administrative costs were $129,037 for Q2 2025 and $335,358 for the six months.
• Cash balance as of June 30, 2025, was $721,661, with $237,739,573 held in the Trust Account.
• The company is a blank check company (SPAC) focused on identifying a business combination target in the healthcare services, healthcare technology, or broader healthcare industry.
• The deadline to complete a business combination is December 11, 2026.

Sentiment

Score: 7

Explanation: The company is performing as expected for a SPAC, generating income from its trust account and maintaining sufficient liquidity. The focus on healthcare is a positive, but the inherent risks of a SPAC (finding a suitable target, geopolitical instability) remain. The increase in redemption value is favorable for shareholders.

Positives

• Generated significant net income from interest on the Trust Account, $2.3 million for Q2 2025 and $4.5 million for the six months.
• Maintained a substantial Trust Account balance of $237.7 million, providing ample capital for a potential business combination.
• Management believes it has sufficient funds for working capital needs for at least one year.
• Disclosure controls and procedures were deemed effective by management.

Negatives

• Operating activities resulted in a net cash outflow of $227,705 for the six months ended June 30, 2025.
• Cash held outside the Trust Account decreased from $949,366 at December 31, 2024, to $721,661 at June 30, 2025.
• The company has not yet identified or commenced operations with a target business, operating solely as a blank check company.
• Current liabilities increased from $357,540 at December 31, 2024, to $441,173 at June 30, 2025.

Risks

• Geopolitical instability from ongoing conflicts (Russia-Ukraine, Israel-Hamas) could lead to market disruptions, volatility in commodity prices, credit and capital markets, supply chain interruptions, and increased cyberattacks.
• Such geopolitical factors could adversely affect the search for an initial business combination and any target business.
• Recent changes in international trade policies and macroeconomic conditions could create global economic consequences.
• The company may be deemed an investment company if it holds investments in the Trust Account for too long, increasing risk.
• Proceeds in the Trust Account could be subject to claims from creditors, potentially having priority over public shareholders.
• There is no assurance that the company will be able to successfully effect a Business Combination within the 24-month completion window (by December 11, 2026).
• If a Business Combination is not completed, public shareholders' rights will be extinguished upon redemption, and rights will expire worthless.
• The Sponsor's liability to indemnify the Trust Account for third-party claims is subject to certain limitations and waivers.
• The company is an early stage and emerging growth company, subject to associated risks.
• The company may need to obtain additional financing if its estimate of costs for identifying and negotiating a Business Combination is insufficient or if a significant number of public shares are redeemed.

Future Outlook

The company continues to seek a business combination target, specifically focusing on the healthcare services, healthcare technology, or broader healthcare industry. It expects to incur significant costs in pursuit of its acquisition plans and does not anticipate generating operating revenues until after a business combination is completed. The deadline for completing a business combination is December 11, 2026.

Management Comments

• We intend to effectuate our Business Combination using cash derived from the proceeds of the Initial Public Offering and the sale of the Private Placement Units, our shares, debt or a combination of cash, shares and debt.
• We expect to continue to incur significant costs in the pursuit of our acquisition plans.
• We do not expect to generate any operating revenues until after the completion of our Business Combination.
• We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business.
• Management believes that the funds which the Company has available following the completion of the initial public offering will enable it to sustain operations for a period of at least one year from the issuance date of these unaudited condensed financial statements.
• Our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2025.

Industry Context

Jackson Acquisition Company II operates as a Special Purpose Acquisition Company (SPAC) with a stated focus on the healthcare sector, including services and technology. This specialization aligns with a broader trend of targeted SPAC formations, aiming to leverage industry-specific expertise for identifying high-quality private companies. The current geopolitical instability and macroeconomic conditions, as noted in the filing, present a challenging environment for SPACs seeking to identify and complete business combinations, potentially impacting deal valuations and investor sentiment across all sectors, including healthcare.

Comparison to Industry Standards

• The company's operational model, generating income solely from interest on its trust account while searching for a target, is standard for a SPAC prior to a business combination.
• The redemption value of Class A shares at $10.34 as of June 30, 2025, compared to the initial IPO price of $10.00, indicates a positive return for public shareholders who choose to redeem, reflecting the interest earned on the trust account. This is a typical feature of well-managed SPACs that invest trust funds in low-risk, interest-bearing securities.
• The 24-month completion window (until December 11, 2026) is a common timeframe for SPACs to identify and consummate a business combination.
• The 80% fair market value rule for the target business relative to trust assets is a standard SPAC requirement.

Related Party Transactions

• Sponsor paid $25,000 for 5,750,000 Class B ordinary shares (Founder Shares).
• Sponsor transferred 200,000 Founder Shares to company officers and directors at their original purchase price.
• An unsecured promissory note for $198,024 is outstanding to the Sponsor, payable upon Business Combination or liquidation.
• The company pays the Sponsor $10,000 per month for office space and administrative/support services, with $67,000 owed as of June 30, 2025.
• The Sponsor, its affiliates, or certain officers and directors may provide Working Capital Loans, convertible into units.

Stakeholder Impact

• Shareholders: Public shareholders benefit from interest accretion in the Trust Account, increasing their potential redemption value (currently $10.34 per share). However, if no Business Combination is completed, rights will expire worthless.
• Sponsor: Has significant equity (Founder Shares) and potential for additional units from Working Capital Loans, but also bears liability for certain third-party claims against the Trust Account.
• Management/Officers/Directors: Received Founder Shares and are compensated for administrative services, aligning their interests with completing a Business Combination.
• Underwriters (Roth Capital Partners): Received an underwriting fee and are entitled to a Business Combination Marketing Fee upon consummation of a Business Combination.
• Prospective Target Businesses: The company's substantial Trust Account provides a significant funding source for a potential acquisition.

Next Steps

• Identify and evaluate a target business for a Business Combination, focusing on healthcare services, healthcare technology, or the broader healthcare industry.
• Perform business due diligence on prospective target businesses.
• Structure, negotiate, and complete a Business Combination by December 11, 2026.
• Continue to manage and monitor interest earned on marketable securities held in the Trust Account.
• Manage and forecast cash to ensure sufficient capital for a Business Combination.

Key Dates

Recommendation

Jackson Acquisition Company II is operating as expected for a SPAC, generating interest income from its trust account, which has increased the redemption value for public shareholders. The company maintains a clear focus on the healthcare sector and has sufficient liquidity for its current operations. However, as a blank check company, its investment thesis hinges entirely on its ability to identify and successfully complete a suitable business combination by December 2026. Until a definitive target is announced, the stock's value is primarily tied to the trust account's per-share value, offering limited upside beyond the accrued interest but also limited downside below the redemption value. Investors should hold while awaiting a potential business combination announcement.

Keywords

SPAC, Jackson Acquisition Company II, 10-Q, Quarterly Report, Healthcare SPAC, Business Combination, Trust Account, Financial Results, SEC Filing, JACS